Dipexium Pharmaceuticals (NASDAQ:DPRX) updated the status of results from two pivotal Phase 3 clinical trials – OneStep-1 and OneStep-2- of its topical antimicrobial peptide, Locilex, for the treatment of diabetic foot ulcers.
Data tables and listings from both of these trials are currently being produced and evaluated by the company’s scientific advisors according to a pre-specified data review procedure.
“We believe the process is nearing completion and anticipate announcing the data later this month after the scientific advisory team informs us of the unblinded results,” president and CEO, David Luci, said in a statement.
